{
    "organizations": [],
    "uuid": "aec8364bba939266bac436ddff21af4fa92b5719",
    "author": "",
    "url": "https://www.reuters.com/article/brief-caladrius-biosciences-doses-first/brief-caladrius-biosciences-doses-first-patient-in-mid-stage-critical-limb-ischemia-trial-in-japan-idUSASC09RZA",
    "ord_in_thread": 0,
    "title": "BRIEF-Caladrius Biosciences Doses First Patient In Mid-Stage Critical Limb Ischemia Trial In Japan",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 13, 2018 / 12:17 PM / in 24 minutes BRIEF-Caladrius Biosciences Doses First Patient In Mid-Stage Critical Limb Ischemia Trial In Japan Reuters Staff 1 Min Read March 13 (Reuters) - Caladrius Biosciences Inc: * CALADRIUS BIOSCIENCES DOSES FIRST PATIENT WITH CLBS12 IN PHASE 2 CRITICAL LIMB ISCHEMIA TRIAL IN JAPAN Source text for Eikon: Further company coverage:",
    "published": "2018-03-13T14:16:00.000+02:00",
    "crawled": "2018-03-13T14:43:19.013+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "pm",
        "minute",
        "bioscience",
        "dos",
        "first",
        "patient",
        "critical",
        "limb",
        "ischemia",
        "trial",
        "japan",
        "reuters",
        "staff",
        "min",
        "read",
        "march",
        "reuters",
        "caladrius",
        "bioscience",
        "inc",
        "caladrius",
        "bioscience",
        "dos",
        "first",
        "patient",
        "clbs12",
        "phase",
        "critical",
        "limb",
        "ischemia",
        "trial",
        "japan",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}